Enveric Biosciences (ENVB)
NASDAQ:ENVB
Want to see ENVB full AI Analyst Report?
ENVB Stock Chart & Stats
$3.72
-$0.12(-23.95%)
At close: 4:00 PM EST
$3.72
-$0.12(-23.95%)
Day’s Range― - ―
52-Week Range$1.42 - $17.63
Previous CloseN/A
Volume362.16K
Average Volume (3M)781.31K
Market Cap
$5.63M
Enterprise Value-$3.54M
Total Cash (Recent Filing)$4.91M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.74
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-27.34
Shares Outstanding3,681,884
10 Day Avg. Volume899,153
30 Day Avg. Volume781,309
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.29
Price to Sales (P/S)0.00
P/FCF Ratio-0.15
Enterprise Value/Market Cap-0.63
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit22.51
Enterprise Value/Ebitda0.44
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-315
Revenue Forecast (FY)$10.00M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetZero recorded debt reduces interest burden and lowers insolvency risk, giving management flexibility on capital allocation. Over a multi-month horizon this structural lack of leverage reduces fixed financial obligations, easing cash runway pressure relative to leveraged peers even as funding needs persist.
Improved Governance And IncentivesStandardized long-term vesting and clarified award terms align executive and director incentives with multi-year value creation and retention, which supports disciplined clinical program execution and can reduce turnover risk. Stronger governance improves investor transparency and decision continuity.
Focused Clinical-stage Pipeline In NeuropsychiatryA focused R&D strategy targeting high-unmet-need CNS indications leverages growing demand for novel neuroplasticity therapies. If clinical programs progress, a concentrated pipeline creates clear development milestones and partnership potential, supporting sustainable long-term franchise value absent commercialization today.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow highlights structural funding needs; absent revenue, ongoing trial and G&A spend will rapidly deplete cash. Over a 2–6 month horizon this elevates refinancing and dilution risk and can force program delays or scope cuts if markets tighten.
Thin Equity And Limited AssetsA small equity base and limited assets constrain the company's ability to self-fund development or absorb setbacks. This structural fragility reduces strategic optionality for multi-stage clinical programs and increases dependence on external capital or partners to sustain operations and milestones.
Dependence On Equity FinancingRepeated use of at-the-market equity raises shows structural reliance on public markets to fund operations. This dilutive financing model can compress shareholder value, and if access to capital becomes constrained, it risks slowing development timelines or forcing unfavorable terms with partners or investors.
Enveric Biosciences News
ENVB FAQ
What was Enveric Biosciences’s price range in the past 12 months?
Enveric Biosciences lowest stock price was $1.42 and its highest was $17.63 in the past 12 months.
What is Enveric Biosciences’s market cap?
Enveric Biosciences’s market cap is $5.63M.
When is Enveric Biosciences’s upcoming earnings report date?
Enveric Biosciences’s upcoming earnings report date is Aug 17, 2026 which is in 62 days.
How were Enveric Biosciences’s earnings last quarter?
Enveric Biosciences released its earnings results on May 15, 2026. The company reported -$1.082 earnings per share for the quarter, missing the consensus estimate of N/A by -$1.082.
Is Enveric Biosciences overvalued?
According to Wall Street analysts Enveric Biosciences’s price is currently Overvalued.
Does Enveric Biosciences pay dividends?
Enveric Biosciences does not currently pay dividends.
What is Enveric Biosciences’s EPS estimate?
Enveric Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Enveric Biosciences have?
Enveric Biosciences has 3,681,884 shares outstanding.
What happened to Enveric Biosciences’s price movement after its last earnings report?
Enveric Biosciences reported an EPS of -$1.082 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.747%.
Which hedge fund is a major shareholder of Enveric Biosciences?
Currently, no hedge funds are holding shares in ENVB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Enveric Biosciences
Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alongside EV102, a cannabinoid cream formulated for topical skin application. Rounding out their portfolio is EV101, a novel combination therapy integrating cannabinoids with chemotherapy. This innovative company is based in Naples, Florida.
Technical Analysis
Biodexa Pharmaceuticals
―
―
Indaptus Therapeutics
―
GT Biopharma
―
Artelo Biosciences
―
Ownership Overview
16.62% Insiders
0.22% Mutual Funds
0.46% Other Institutional Investors
81.42% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---